Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

作者：Adam S. Kittai, Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond, Danielle M. Brander, John C. Byrd, Julio C. Chávez, Elise A. Chong, Matthew S. Davids, Alexey V. Danilov, Wei Ding, Mark R. Dowling, Kaitlyn Dvorak‐Kornaus, Hannah Freedman, Paul J. Hampel, Carrie Ho, Steven R. Hwang, Prioty Islam, Nikita Malakhov, Matthew J. Matasar, Cecelia Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Philipp W. Raess, Manoj Rai, Lindsey E. Roeker, Joanna Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Hamish W. Scott, Mazyar Shadman, Geoffrey Shouse, Alan P Skarbnik, Stephen E. Spurgeon, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, Max Yano, Jennifer A. Woyach · 发表于：Blood Cancer Journal · 年份：2025 · DOI：10.1038/s41408-025-01236-6 · 被引用次数：13 · 研究领域：Chronic Lymphocytic Leukemia Research、Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders

Richter transformation (RT) is an infrequent but consequential event that can occur at any time for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). RT is defined by the development of an aggressive lymphoma, most often diffuse large B-cell Lymphoma (DLBCL) [ 1 ]. Targeted therapies such as Bruton Tyrosine Kinase inhibitors (BTKi) and B-cell leukemia/lymphoma 2 inhibitors (BCL2i) have improved survival for patients with CLL, but not for patients with RT [ 2 , 3 ].